WallStSmart

Medtronic PLC (MDT)vsTriSalus Life Sciences Inc. (TLSI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 78490% more annual revenue ($35.48B vs $45.15M). MDT leads profitability with a 13.0% profit margin vs -86.9%. MDT earns a higher WallStSmart Score of 56/100 (C).

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0

TLSI

Avoid

25

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Intrinsic value data unavailable for TLSI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

TLSI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
59.8%10/10

Revenue surging 59.8% year-over-year

Areas to Watch

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

TLSI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$238.48M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-5.0%2/10

ROE of -5.0% — below average capital efficiency

Free Cash FlowQuality
$-2.52M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bull Case : TLSI

The strongest argument for TLSI centers on Revenue Growth. Revenue growth of 59.8% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Bear Case : TLSI

The primary concerns for TLSI are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MDT profiles as a value stock while TLSI is a hypergrowth play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.73 — expect wider price swings.

TLSI is growing revenue faster at 59.8% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 25/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

TriSalus Life Sciences Inc.

HEALTHCARE · MEDICAL DEVICES · USA

TriSalus Life Sciences Inc. (TLSI) is a cutting-edge biopharmaceutical firm committed to transforming cancer therapies through its proprietary localized drug delivery technologies. By enhancing the efficacy of immuno-oncology agents and overcoming significant distribution barriers within the tumor microenvironment, TriSalus aims to significantly improve patient outcomes in oncology. The company is advancing a robust pipeline of clinical programs that reflect its innovative approach and dedication to addressing the unmet needs of patients with challenging cancers. With a focus on expanding access to effective therapies, TriSalus is well-positioned to make a meaningful impact in the field of cancer treatment.

Want to dig deeper into these stocks?